No Data
Shanwaishan (688410.SH): The USA's tariff policy has no impact on the company's existing sales business.
On April 7, Glonghui reported that Shanwaishan (688410.SH) stated on an interactive platform regarding the impact of USA's tariff policies on the company, based on the current operating situation of Shanwaishan. First, USA's tariff policies do not affect the company's international sales as the company has not yet ventured into the USA market. Currently, the company's overseas business is focused on high-growth Emerging Markets. Data published for 2024 (the company's third quarter report) indicates that the company plans to maintain the high growth momentum of its dialysis equipment in the Asia-Pacific region while vigorously developing markets in South America, Africa, and Europe, utilizing overseas Asia Vets Big Data platforms and after-sales service systems to build.
Mountain Wai Mountain: 2024 Annual Results Report Announcement
2024 Annual Results Express Announcement
Shanwai Mountain (688410.SH): Net income for the year 2024 is 74.0625 million yuan, a decrease of 61.92% year-on-year.
On February 27, Glonghui reported that Shanwaishan (688410.SH) released its performance quick report for 2024. During the reporting period, the company achieved revenue of 567.2754 million yuan, a decrease of 17.80% compared to the same period last year; it realized a net income attributable to the parent company's owners of 74.0625 million yuan, a decrease of 61.92% compared to the same period last year; it achieved a net income attributable to the parent company's owners after deducting non-operating gains and losses of 60.3541 million yuan, a decrease of 65.73% compared to the same period last year. In 2023, due to the promotion of critical illness capacity building policies, the company's high gross margin product—continuous blood purification.
Shanwai Shan (688410.SH) plans to use no more than 0.48 billion yuan (inclusive) of idle self-owned funds for Cash / Money Market management.
On February 23, Gelonghui reported that Mountain Outside Mountain (688410.SH) announced that Chongqing Mountain Outside Mountain Blood Purification Technology Co., Ltd. (hereinafter referred to as "the company") and its subsidiaries plan to use no more than 0.48 billion yuan (including) of idle self-owned funds for cash management. The cash management period for the idle self-owned funds is within twelve months from the date of review and approval by the Board of Directors, and funds can be used in a revolving manner within the above limits and period.
Express News | Sws Hemodialysis Care Says Key Shareholder Plans to Unload up to 2.92% Stake in Three Months
SWS Hemodialysis Care Co., Ltd.'s (SHSE:688410) Shares Not Telling The Full Story
